- Home
- ALRN vs ECOR Comparison
ALRN vs ECOR Comparison
Compare ALRN & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALRN
- ECOR
- Stock Information
- Founded
- ALRN 2001
- ECOR 2005
- Country
- ALRN United States
- ECOR United States
- Employees
- ALRN N/A
- ECOR N/A
- Industry
- ALRN Biotechnology: Pharmaceutical Preparations
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ALRN Health Care
- ECOR Health Care
- Exchange
- ALRN Nasdaq
- ECOR Nasdaq
- Market Cap
- ALRN 76.9M
- ECOR 65.0M
- IPO Year
- ALRN 2017
- ECOR 2018
- Fundamental
- Price
- ALRN $1.92
- ECOR $13.93
- Analyst Decision
- ALRN Strong Buy
- ECOR Strong Buy
- Analyst Count
- ALRN 1
- ECOR 1
- Target Price
- ALRN $19.00
- ECOR $15.00
- AVG Volume (30 Days)
- ALRN 92.8K
- ECOR 97.7K
- Earning Date
- ALRN 11-14-2024
- ECOR 11-13-2024
- Dividend Yield
- ALRN N/A
- ECOR N/A
- EPS Growth
- ALRN N/A
- ECOR N/A
- EPS
- ALRN N/A
- ECOR N/A
- Revenue
- ALRN N/A
- ECOR $23,327,000.00
- Revenue This Year
- ALRN N/A
- ECOR $61.40
- Revenue Next Year
- ALRN N/A
- ECOR $38.43
- P/E Ratio
- ALRN N/A
- ECOR N/A
- Revenue Growth
- ALRN N/A
- ECOR 74.10
- 52 Week Low
- ALRN $1.61
- ECOR $5.25
- 52 Week High
- ALRN $7.42
- ECOR $15.25
- Technical
- Relative Strength Index (RSI)
- ALRN 29.69
- ECOR 61.01
- Support Level
- ALRN $1.85
- ECOR $13.22
- Resistance Level
- ALRN $2.38
- ECOR $14.87
- Average True Range (ATR)
- ALRN 0.30
- ECOR 1.25
- MACD
- ALRN -0.01
- ECOR 0.19
- Stochastic Oscillator
- ALRN 6.31
- ECOR 71.57
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.